---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-122272"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2025-12-18T23:59:59+00:00"
generated_at: "2026-05-16T12:43:16.144697+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sagimet announces positive Phase 1 PK data for denifanstat/resmetirom combo in MASH

## Summary
- Phase 1 PK trial (NCT07216313) of denifanstat + resmetirom in 40 healthy adults met objectives; combination well-tolerated, no SAEs.
- PK data support further development; no drug-drug interaction signals observed; no treatment discontinuations.
- Company plans Phase 2 proof-of-concept trial in MASH F4 fibrosis patients in 2H 2026 pending regulatory consultation.
- Global license agreement with TAPI (TEVA affiliate) to develop once-daily fixed-dose combination tablet for Phase 3.

## SEC filing metadata
- accession: 0001104659-25-122272
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2025-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465925122272/0001104659-25-122272-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465925122272/tm2533462d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-122272
- JSON: https://secwatch.observer/filing/0001104659-25-122272.json
- Plain text: https://secwatch.observer/filing/0001104659-25-122272.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.